Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6890MR)

This product GTTS-WQ6890MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6890MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5842MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ11887MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3586MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ14143MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ15096MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ12165MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ676MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ12245MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MPDL3280A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW